| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-13,205 | -11,876 | -9,805 | -3,926 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
199 | 68 | 18 | 6 | |||
Stock-based compensation | ||||||
1,537 | 1,140 | 707 | 324 | |||
License rights expense settled in stock | ||||||
490 | 0 | - | - | |||
Gain from sale of fixed assets | ||||||
1 | 0 | - | - | |||
Deferred compensation - related party | ||||||
- | - | 62 | 87 | |||
Gain from change in fair value of warrant liability | ||||||
-4,062 | -3,185 | 2,548 | 0 | |||
Operating lease, net of sublease receipts | ||||||
14 | - | - | - | |||
Gain in settlement of liability | ||||||
- | - | 149 | 0 | |||
Gain from expiration of warrants | ||||||
- | - | 1,238 | 0 | |||
Loss on foreign currency transactions | ||||||
0 | 40 | 0 | - | |||
Other | ||||||
- | - | 9 | 0 | |||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
1,909 | 252 | 364 | 215 | |||
Accounts payable | ||||||
907 | 436 | 411 | -41 | |||
Accrued expenses and other current liabilities | ||||||
-1,140 | 1,400 | 495 | 0 | |||
Other long-term liabilities | ||||||
0 | 26 | 0 | - | |||
Net cash used in operating activities | ||||||
-17,198 | -12,203 | -7,324 | -3,765 | |||
Cash flows from investing activities: | ||||||
Purchase of fixed assets | ||||||
52 | 417 | 28 | 21 | |||
Proceeds from sale of fixed assets | ||||||
1 | 0 | - | - | |||
Acquisition of Moleculin, LLC, net | ||||||
- | - | - | 100 | |||
Net cash used in investing activities | ||||||
-51 | -417 | -28 | -121 | |||
Cash flows from financing activities: | ||||||
Proceeds from exercise of stock options | ||||||
5 | 5 | 0 | - | |||
Proceeds from notes payable | ||||||
- | - | - | 165 | |||
Payments on notes payable | ||||||
- | - | - | 470 | |||
Proceeds from exercise of warrants | ||||||
1,557 | 15 | 3,988 | 0 | |||
Proceeds from sale of common stock, net of issuance costs | ||||||
19,292 | 12,025 | 6,071 | 9,170 | |||
Net cash provided by financing activities | ||||||
20,854 | 12,045 | 10,059 | 8,865 | |||
Effect of exchange rate changes on cash and cash equivalents | ||||||
-4 | -5 | - | - | |||
Net change in cash and cash equivalents | ||||||
3,601 | -580 | - | - | |||
Effect of exchange rate changes on cash and cash equivalents | ||||||
- | - | 0 | - | |||
Net change in cash and cash equivalents | ||||||
- | - | 2,707 | 4,979 | |||
Supplemental disclosures of cash flow information: | ||||||
Cash paid for interest | ||||||
1 | 5 | 3 | - | |||
Cash paid for interest | ||||||
- | - | - | 5 | |||
Cash paid for taxes | ||||||
19 | 21 | 0 | 0 | |||
Non-cash investing and financing activities: | ||||||
Purchases of property and equipment in accounts payable and accrued liabilities | ||||||
22 | 23 | 0 | - | |||
Leasehold improvements paid by landlord | ||||||
0 | 82 | 0 | - | |||
Research and development costs settled in stock | ||||||
490 | 0 | - | - | |||
Common stock issued for the Acquisition of Moleculin, LLC | ||||||
- | - | - | 9,774 | |||
Common stock issued for conversion of debt | ||||||
- | - | 302 | 364 | |||
Warrants issued for services provided | ||||||
- | - | 104 | 375 | |||
Common stock issued for services provided | ||||||
- | - | 89 | 158 | |||